RSC Advances
Paper
3
.2.2. Preparation of Fe
a round bottom ask (50 mL), the particles of Fe
g) were dispersed in chloroform (10 mL), and the temperature 130.0, 129.5, 126.7, 115.4, 47.0, 46.9, 46.3, 31.7, 31.2, 28.9, 27.8.
3
O
4
@acacia–SO
3
H nano-powder. In (m, 2H), 2.34 (d, 2H), 2.32 (d, 2H), 2.31 (d, 2H), 1.14 (s, 6H), 1.07
1
3
3 4
O
@acacia (0.6 (s, 6H). C NMR (75 MHz, DMSO), d (ppm): 189.8, 135.3, 134.1,
was reduced by an ice bath. In a separate ask, chlorosulfonic
9-(3-Methylphenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahy-
acid (99%) (2.0 mL) was mixed with chloroform (2.0 mL), and droacridine-1,8(2H,5H)-dione (product e): M. P ( C): 211–213.
ꢂ
1
the resulting solution was added dropwise to the main reaction
ask with stirring. Aer completion of the addition, the ice bath 7.09–7.11 (d, 1H), 7.03–7.08 (m, 1H), 6.86–6.88 (d, 1H), 5.05 (s,
was removed, and vigorous stirring was continued for an 1H), 2.32–2.40 (m, 2H), 2.26 (d, 2H), 2.22 (d, 2H), 2.16 (d, 2H),
H NMR (300 MHz, DMSO), d (ppm): 8.07 (s, 1H), 7.26 (s, 1H),
1
3
additional 2 h at room temperature. Ultimately, the product was 1.05 (s, 6H), 0.95 (s, 6H). C NMR (75 MHz, DMSO), d (ppm):
magnetically separated, washed, and dried as described above. 196.1, 149.5, 146.7, 137.3, 129.1, 128.0, 126.9, 125.2, 113.3, 51.1,
3
.2.3. General procedure for the catalyzed synthesis of 9- 40.8, 33.6, 32.7, 29.8, 27.2, 21.8.
phenyl hexahydroacridine pharmaceutical derivatives. In
9-(3-Methoxyphenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahy-
a round bottom ask (25 mL), aldehyde (1.0 mmol), dimedone droacridine-1,8(2H,5H)-dione (product f): M. P ( C): 301–303. H
2.0 mmol), ammonium acetate salt (1.1 mmol), and Fe O @- NMR (300 MHz, DMSO), d (ppm): 8.94 (s, 1H), 7.25 (s, 1H), 7.22
ꢂ
1
(
3
4
acacia–SO H nano-powder (0.02 g) were mixed in ethanol (2.0 (d, 1H), 7.01 (m, 1H), 6.98 (d, 1H), 5.07 (s, 1H), 3.91 (s, 3H), 2.22–
3
mL), and the mixture was reuxed. Aer the appropriate time 2.27 (m, 2H), 2.17 (d, 2H), 2.11 (d, 2H), 2.04 (d, 2H), 1.12 (s, 6H),
1
3
had passed (110 min), the particles of the catalytic system were 0.95 (s, 6H). C NMR (75 MHz, DMSO), d (ppm): 196.1, 158.72,
magnetically removed and the desired product was puried via 149.9, 143.8, 134.9, 128.5, 127.7, 125.2, 112.8, 50.8, 40.2, 33.0,
1
13
ash-column chromatography. The original H and C-NMR 32.3, 29.4, 27.9, 20.9.
spectra of the selected products are shown in Fig. S1–S20 in
the ESI† section.
9-(4-Nitrophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahy-
droacridine-1,8(2H,5H)-dione (product g): M. P ( C): 286–288.
ꢂ
3
.2.4. Recycling of the catalyst. Aer completion of the rst 1H NMR (300 MHz, DMSO), d (ppm): 9.90 (s, 1H), 7.19–7.21 (d,
round, the Fe O @acacia–SO H particles were magnetically 2H), 7.12–7.14 (d, 2H), 4.76 (s, 1H), 2.42–2.49 (d, 4H), 2.14–2.32
3
4
3
1
3
separated and the rest were separated via decanting. Then, the (d, 2H), 1.95–1.98 (d, 2H), 0.99 (s, 6H), 0.84 (s, 6H). C NMR (75
particles were washed well with deionized water and ethanol (20 MHz, DMSO), d (ppm): 194.4, 149.5, 146.1, 129.9, 129.5, 127.5,
mL) four successive times. Aerward, the particles were died in 115.5, 111.1, 50.1, 40.0, 32.6, 32.2, 29.0, 26.4.
a vacuum oven for 24 h. To reuse the particles, redispersion was
3,3,6,6-Tetramethyl-9-(3-nitrophenyl)-3,4,6,7,9,10-hexahy-
initially performed by an ultrasound cleaner bath (50 kHz, droacridine-1,8(2H,5H)-dione (product h): M. P ( C): 281–283.
ꢂ
ꢀ
1
1
2
00 W L ); then, the reactants were added to the ask.
H NMR (300 MHz, DMSO), d (ppm): 9.31 (s, 1H), 8.00–8.01 (d,
H), 7.65–7.66 (d, 1H), 7.54–7.57 (t, 1H), 4.65 (s, 1H), 2.50–2.59
2
(
(
dd, 4H), 2.27–2.30 (d, 2H), 2.08–2.12 (d, 2H), 1.04 (s, 6H), 0.91
s, 6H). C NMR (75 MHz, DMSO), d (ppm): 196.0, 149.4, 149.0,
3.3. Spectral data for selected products
13
3
1
,3,6,6-Tetramethyl-9-phenyl-3,4,6,7,9,10-hexahydroacridine-
,8(2H,5H)-dione (product a): M. P ( C): 279–281. H NMR (300
131.1, 129.7, 122.3, 112.9, 51.0, 40.9, 33.9, 32.8, 29.7, 27.3, 21.1.
9-(4-Methoxyphenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahy-
ꢂ
1
ꢂ
1
MHz, DMSO), d (ppm): 9.30 (s, 1H), 7.00–7.13 (m, 5H), 4.60 (s, droacridine-1,8(2H,5H)-dione (product i): M. P ( C): 288–290. H
1
0
1
2
H), 2.40–2.48 (m, 2H), 2.27 (d, 2H), 2.12 (d, 2H), 2.00 (d, 2H), NMR (300 MHz, DMSO), d (ppm): 9.20 (s, 1H), 7.05–7.07 (t, 2H),
.98 (s, 6H), 0.83 (s, 6H). C NMR (75 MHz, DMSO), d (ppm): 6.76–6.80 (t, 2H), 4.46 (s, 1H), 3.70 (s, 3H), 2.56 (d, 2H), 2.49–
94.3, 149.3, 147.1, 127.6, 127.5, 125.4, 111.4, 50.2, 32.9, 32.2, 2.51 (m, 2H), 2.27 (d, 2H), 2.09 (d, 2H), 1.03 (s, 6H), 0.91 (s, 6H).
1
3
1
3
9.1, 26.4.
-(2-Chlorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahy-
droacridine-1,8(2H,5H)-dione (product b): M. P ( C): 264–266.
C NMR (75 MHz, DMSO), d (ppm): 196.2, 157.5, 149.6, 139.2,
9
128.8, 125.2, 113.0, 50.8, 40.36, 32.6, 32.4, 29.5, 26.9.
9-(4-Bromophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahy-
H NMR (300 MHz, DMSO), d (ppm): 9.59 (s, 1H), 7.25–7.27 (d, droacridine-1,8(2H,5H)-dione (product j): M. P ( C): 321–324. H
H), 7.10–7.20 (m, 1H), 7.04–7.08 (m, 1H), 6.99–7.01 (m, 1H), NMR (300 MHz, DMSO), d (ppm): 9.33 (s, 1H), 7.23–7.26 (dd,
2H), 6.87–6.92 (m, 2H), 4.73 (s, 1H), 2.26–2.46 (m, 4H), 2.19–2.22
NMR (75 MHz, DMSO), d (ppm): 196.4, 152.4, 142.6, 132.0, (m, 2H), 2.15 (m, 4H), 1.10 (s, 6H), 0.99 (s, 6H). C NMR (75
ꢂ
1
ꢂ
1
1
5
1
3
.05 (s, 1H), 2.71–2.10 (m, 8H), 0.98 (s, 6H), 0.92 (s, 6H).
C
1
3
129.7, 128.2, 115.2, 50.6, 40.8, 32.2, 31.4, 29.3, 27.2.
MHz, DMSO), d (ppm): 194.4, 149.6, 149.3, 147.1, 127.9, 127.8,
9
-(4-Chlorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahy-
126.0, 111.9, 50.7, 32.2, 31.2, 29.2, 27.3.
ꢂ
droacridine-1,8(2H,5H)-dione (product c): M. P ( C): 290–292.
H NMR (300 MHz, DMSO), d (ppm): 9.92 (s, 1H), 7.27–7.30 (d,
H), 7.18–7.19 (d, 2H), 4.50 (s, 1H), 2.50–2.59 (dd, 4H), 2.25–2.28
d, 2H), 2.07–2.10 (d, 2H), 1.04 (s, 6H), 0.90 (s, 6H). C NMR (75 In this work, we designed and fabricated a novel catalytic
1
4. Conclusions
2
(
1
3
MHz, DMSO), d (ppm): 196.1, 149.3, 147.1, 131.7, 129.6, 129.3, system with high heterogeneity and magnetic features to facil-
1
28.2, 113.1, 50.2, 33.6, 32.8, 29.1, 27.3.
itate the MCR synthetic reactions of 9-phenyl hexahy-
droacridine pharmaceutical derivatives. A combination of
9-(2,4-Dichlorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hex-
ꢂ
ahydroacridine-1,8(2H,5H)-dione (product d): M. P ( C): 318– acacia gum (gum arabic) with iron oxide magnetic particles on
1
3
1
20. H NMR (300 MHz, DMSO), d (ppm): 9.95 (s, 1H), 7.34 (s, the nanoscale was used as a magnetized natural matrix. From
H), 7.28–7.33 (d, 1H), 7.19–7.22 (d, 1H), 5.58 (s, 1H), 2.38–2.43 the physicochemical aspect, through effective H-binding
40064 | RSC Adv., 2020, 10, 40055–40067
This journal is © The Royal Society of Chemistry 2020